0001572426-19-000131.txt : 20191015 0001572426-19-000131.hdr.sgml : 20191015 20191015171356 ACCESSION NUMBER: 0001572426-19-000131 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191010 FILED AS OF DATE: 20191015 DATE AS OF CHANGE: 20191015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RAWLINGS DARRYL CENTRAL INDEX KEY: 0001611679 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36537 FILM NUMBER: 191151557 MAIL ADDRESS: STREET 1: 6100 4TH AVENUE SOUTH STREET 2: SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TRUPANION, INC. CENTRAL INDEX KEY: 0001371285 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6100 4TH AVENUE SOUTH STREET 2: SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98108 BUSINESS PHONE: 888-733-2685 MAIL ADDRESS: STREET 1: 6100 4TH AVENUE SOUTH STREET 2: SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98108 FORMER COMPANY: FORMER CONFORMED NAME: TRUPANION INC. DATE OF NAME CHANGE: 20131114 FORMER COMPANY: FORMER CONFORMED NAME: VETINSURANCE INTERNATIONAL INC DATE OF NAME CHANGE: 20060802 4 1 wf-form4_157117400771062.xml FORM 4 X0306 4 2019-10-10 0 0001371285 TRUPANION, INC. TRUP 0001611679 RAWLINGS DARRYL C/O TRUPANION, INC. 6100 4TH AVENUE SOUTH, SUITE 200 SEATTLE WA 98108 1 1 0 0 President and CEO Common Stock 2019-10-10 4 S 0 4000 21.4265 D 1454499 D The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 13, 2018, in order to implement a plan of financial diversification. Accordingly, the reporting person had no discretion with regard to the timing of the transaction. In aggregate, the reporting person's plan is Rule 10b5-1 trading plan is part of a diversification strategy on the part of the reporting person to diversify up to 25% of the reporting person's holdings as of the date of the Company's initial public offering in July 2014 from the inception of the Rule 10b5-1 trading plan through 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.15 to $21.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2). /s/ Jennifer Tornow as attorney-in-fact for Darryl Rawlings 2019-10-15